^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    carboplatin

    i
    Other names: CBDCA, JM-8, JM8, NSC-241240, NSC-241240, NSC 241240, NSC-241-240
    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    1d
    IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) (clinicaltrials.gov)
    P2, N=70, Recruiting, Innate Pharma | Trial completion date: Sep 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression • KRAS mutation • EGFR mutation • ALK mutation
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • pemetrexed • IPH5201
    1d
    Morpheus-TNBC: A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=1132, Recruiting, Hoffmann-La Roche | N=792 --> 1132
    Enrollment change
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • Ibrance (palbociclib) • carboplatin • gemcitabine • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Verzenio (abemaciclib) • albumin-bound paclitaxel • Kisqali (ribociclib) • fulvestrant • eribulin mesylate • letrozole • ipatasertib (RG7440) • Trodelvy (sacituzumab govitecan-hziy) • Itovebi (inavolisib) • giredestrant (RG6171) • Actemra IV (tocilizumab) • atirmociclib (PF-07220060) • ladiratuzumab vedotin (SGN-LIV1A) • selicrelumab (RG7876)
    1d
    A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Primary Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov)
    P4, N=100, Not yet recruiting, GlaxoSmithKline
    New P4 trial
    |
    carboplatin • paclitaxel • Jemperli (dostarlimab-gxly)
    1d
    CHORUS: A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer (clinicaltrials.gov)
    P2, N=41, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • Ilaris (canakinumab)
    1d
    Acute Abdomen Secondary to Ileal Perforation As the Initial Presentation of Advanced Müllerian Malignancy With Hepatic Metastasis: A Case Report. (PubMed, Cureus)
    The patient received combination chemotherapy with gemcitabine, carboplatin, and bevacizumab, achieving a near-complete metabolic response. Immunohistochemistry plays a crucial role in identifying the primary tumor origin. Management requires a staged approach with emergency surgical intervention followed by multidisciplinary oncological treatment for optimal outcomes.
    Journal
    |
    PAX8 (Paired box 8)
    |
    Avastin (bevacizumab) • carboplatin • gemcitabine
    1d
    Sarcomatoid Transformation of Pulmonary Mucinous Adenocarcinoma as a Mechanism of Immunotherapy Resistance. (PubMed, Thorac Cancer)
    As surgical resection was not feasible, first-line treatment with ipilimumab plus nivolumab combined with chemotherapy was initiated, resulting in a partial response...Thirteen months later, the patient developed radiographic worsening of ILD, for which oral prednisolone was initiated...The patient received two cycles of nab-paclitaxel plus carboplatin without response and subsequently died. These findings emphasize that clinicians should recognize that IMA may undergo sarcomatous transformation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • NKX2-1 (NK2 Homeobox 1) • VIM (Vimentin)
    |
    BRAF mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • albumin-bound paclitaxel • prednisolone
    1d
    Metabolic activation of LDHA by ERRα represses inflammasome-dependent pyroptosis and promotes ovarian cancer chemoresistance. (PubMed, Cell Death Dis)
    Scanning electron microscopy, immunofluorescence, Western Blot, and other molecular functional assays show that the ERRα/LDHA axis drives lactate accumulation, downregulates inflammasome-related proteins (NLRP3, caspase-1, GSDMD and GSDMD-N), thereby suppressing pyroptosis and promoting resistance to cisplatin, carboplatin, and paclitaxel in ovarian cancer cells. Created in BioRender. Ren, Y. (2025) https://BioRender.com/qeh0dw8.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    LDH elevation
    |
    cisplatin • carboplatin • paclitaxel
    1d
    NCI-2018-01071: Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC (clinicaltrials.gov)
    P2, N=96, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed
    Trial completion
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Lynparza (olaparib) • carboplatin • prednisone • cabazitaxel
    2d
    Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=12, Completed, Northwestern University | Recruiting --> Completed | N=100 --> 12
    Trial completion • Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    CELLSEARCH®
    |
    Keytruda (pembrolizumab) • carboplatin
    3d
    Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=156, Completed, National Cancer Institute (NCI) | Phase classification: P2 --> P1/2
    Phase classification
    |
    cisplatin • carboplatin • sunitinib • etoposide IV
    3d
    Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Suspended, David Bond, MD | Recruiting --> Suspended
    Trial suspension
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    carboplatin • lenalidomide • cyclophosphamide • ifosfamide • etoposide IV • Monjuvi (tafasitamab-cxix)
    4d
    Machine learning-based identification of an oxidative phosphorylation signature for prognosis, immune infiltration, and drug sensitivity in ovarian cancer. (PubMed, Front Immunol)
    Additionally, higher OPRGS was associated with lower cancer stemness indices, resistance to paclitaxel but sensitivity to carboplatin, revealing complex biological behaviors of the tumor. This study constructed a new OPRGS for OC. It may serve as a potential indicator for predicting prognosis, immune infiltration, and chemotherapy drug sensitivity in OC patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    carboplatin • paclitaxel